Treatment strategy of EGFR-mutated non-small cell lung cancer

被引：1

作者：

Tanaka, Fumihiro ^{[1
]}

Yoneda, Kazue ^{[1
]}

Takenaka, Masaru ^{[1
]}

Kuroda, Koji ^{[1
]}

机构：

[1] Univ Occupat & Environm Hlth, Dept Surg Chest Surg 2, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan

来源：

JOURNAL OF THORACIC DISEASE | 2022年 / 14卷 / 03期

关键词：

OSIMERTINIB; PATIENT; MUTATIONS; SURGERY;

D O I：

10.21037/jtd-22-177

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：602 / 606

页数：5

共 50 条

[41] Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
Brueckl, Wolfgang M.
Reck, Martin
Griesinger, Frank
Schaefer, Harald
Kortsik, Cornelius
Gaska, Tobias
Rawluk, Justyna
Krueger, Stefan
Kokowski, Konrad
Budweiser, Stephan
Ficker, Joachim H.
Hoffmann, Christopher
Schueler, Andrea
Laack, Eckart
[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[42] Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
Huo, Gengwei
Song, Ying
Liu, Wenjie
Cao, Xuchen
Chen, Peng
[J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
[43] Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer
Shiozawa, Toshihiro
Numata, Takeshi
Tamura, Tomohiro
Endo, Takeo
Kaburagi, Takayuki
Yamamoto, Yusuke
Yamada, Hideyasu
Kikuchi, Norihiro
Saito, Kazuhito
Inagaki, Masaharu
Kurishima, Koichi
Funayama, Yasunori
Miyazaki, Kunihiko
Koyama, Nobuyuki
Furukawa, Kinya
Nakamura, Hiroyuki
Kikuchi, Shinji
Ichimura, Hideo
Sato, Yukio
Sekine, Ikuo
Satoh, Hiroaki
Hizawa, Nobuyuki
[J]. ANTICANCER RESEARCH, 2022, 42 (05) : 2583 - 2590
[44] Non-small-cell lung cancer: how to manage EGFR-mutated disease
Pecci, Federica
Cantini, Luca
Metro, Giulio
Ricciuti, Biagio
Lamberti, Giuseppe
Farooqi, Ammad Ahmad
Berardi, Rossana
[J]. DRUGS IN CONTEXT, 2022, 11
[45] Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation
Mak, D. Y.
Yan, M.
Cheung, P.
Parmar, A.
Poon, I.
Ung, Y.
Tsao, M.
Warner, A.
Louie, A. V.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S497 - S497
[46] Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
Bertoli, Elisa
De Carlo, Elisa
Del Conte, Alessandro
Stanzione, Brigida
Revelant, Alberto
Fassetta, Kelly
Spina, Michele
Bearz, Alessandra
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
[47] Factors Associated With Distant Metastasis in EGFR-mutated Non-small Cell Lung Cancer Patients: Logistic Analysis
Watanabe, Hiroko
Okauchi, Shinichiro
Miyazaki, Kunihiko
Satoh, Hiroaki
Hizawa, Nobuyuki
[J]. IN VIVO, 2019, 33 (04): : 1369 - 1372
[48] Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer
Yamada, Tadaaki
Hirai, Soichi
Katayama, Yuki
Yoshimura, Akihiro
Shiotsu, Shinsuke
Watanabe, Satoshi
Kikuchi, Toshiaki
Hirose, Kazuki
Kubota, Yutaka
Chihara, Yusuke
Harada, Taishi
Tanimura, Keiko
Takeda, Takayuki
Tamiya, Nobuyo
Kaneko, Yoshiko
Uchino, Junji
Takayama, Koichi
[J]. CANCER MEDICINE, 2019, 8 (04): : 1521 - 1529
[49] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
Nio, Yuta
Ishida, Hiroo
Matsumoto, Natsumi
Kusumoto, Sojiro
Kubota, Yutaro
Tsunoda, Takuya
Sasaki, Yasutsuna
Fujita, Ken-ichi
[J]. BMC PULMONARY MEDICINE, 2022, 22 (01)
[50] Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
Koulouris, Andreas
Tsagkaris, Christos
Corriero, Anna Chiara
Metro, Giulio
Mountzios, Giannis
[J]. CANCERS, 2022, 14 (14)

← 1 2 3 4 5 →